State of Research
Quality of Conclusions
TBD Papers studying this directly
TBD Companies working on this
Make Blossom Sustainable
Blossom is free to use and will always be.
Supporting Blossom makes this possible. When you support Blossom for €20/month, you get access to our downloadable files, influence over the direction of our 'psychedelics and ...' pages, and future projects.
Our vision is that psychedelics can be used worldwide to better the lives of as many as 450 million people who suffer from mental health problems. Our information hopes to make that vision come to life just a little faster.
Here will be a narrative, readable, summary of the research.
In our literature study we came across the following studies of note. Browse the meta, review, commentary articles for an overview. Check out the individual studies for specific experiments and observations.
Prosocial effects of MDMA: A measure of generosity
2015| de Wit, H., Delton, A. W., Kirkpatrick, M. G., Robertson, T. E.
This placebo-controlled within-subjects study (n=32) investigated the dose-dependent effects of MDMA (35-70mg/70kg) on generosity, as measured by their willingness to trade-off personal welfare in favor of the welfare of someone else. The higher dose of MDMA increased generosity in relation to a close friend but not a stranger, whereas the lower dose did not affect generosity toward the friend but slightly increased generosity toward a stranger. These results are in line with the prosocial effects of oxytocin, which promotes trust amongst members of a social ingroup but not the out-group.
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers
2019| Carhart-Harris, R. L., Erritzoe, D., Fisher, P. M., Frokjaer, V. G., Knudsen, G. M., Smith, J. M.
This cross-sectional study (n=45) evaluates associations between recreational use of psychedelics and MDMA and (a) personality measures and (b) key markers of cerebral serotonergic signaling (serotonin transporter and serotonin-2A-receptor binding).
Neuroticism is associated with challenging experiences with psilocybin mushrooms
2017| Barrett, F. S., Griffiths, R. R., Johnson, M. W.
This survey study (n=2,974) found that neurotic individuals may be more likely to have a challenging experience with psilocybin.
Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study
2012| Alcázar, M. A., Araújo, D. B., Barbanoj, M. J., Barbosa, P., Bouso, J. C., Cutchet, M., Fábregas, J. M., Fernández, X., Fondevila, S., González, D., Riba, J.
This longitudinal field study (n=242) assessed personality, mental health, life attitudes, and neuropsychological performance in a large number of long-term ritual ayahuasca users and control participants that were matched for age, sex, educational level, and religious background. Long-term ayahuasca use indicated a lower presence of psychopathological symptoms, better performance in neuropsychological tests, higher degrees of spirituality, and better psychosocial adaptation as reflected by some attitudinal traits such as Purpose in Life and Subjective Well-Being, and benefits on mental health were still observable in a one-year follow-up.
Effects of psilocybin therapy on personality structure
2018| Carhart-Harris, R. L., Erritzoe, D., Kaelen, M., MacLean, K. A., Nour, M. R., Nutt, D. J., Roseman, L.
This open-label study (n=20) found that dosages of psilocybin (10, 25mg) in a supportive setting, for those with treatment-resistant depression (TRD), changed their personality. At 3-month follow-up, Neuroticism was decreased, Extraversion and Openness were increased. The changes were similar (but more pronounced) to changes after conventional antidepressant treatment.
This section compares the research with psychedelics to other therapies, medicines, or treatments.
This section highlights the various measures used and their use in research.
Who are the top researches in this area, the ones who have done the groundbreaking research.
What do we not know at this time? Where are the gaps in our knowledge and are we closing it?
The companies that are actively engaged in researching this topic or (planning to) provide therapy focussed on this topic.
This section highlights everything done outside of academia, from popular press to books and non academic research.